Ad
related to: regeneron approved drugs- Genetic Research
Speeding Drug Discovery
Learn about the RGC
- Antibodies at Work
End-to-End Research & Development
See Regeneron's Approved Medicines
- About Regeneron
Industry-Leading Biotechnology
Reinventing Drug Discovery
- Science & Technology
See Regeneron's New Technology
Turning Science into Medicine
- Genetic Research
Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [26] [27] The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians. [26]
Regeneron Pharmaceuticals (NAS: REGN) has gained Food and Drug Administration approval of its third drug, Zaltrap, which treats metastatic colorectal cancer. Three approvals in four years is no ...
(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at ...
The FDA granted the approval of Inmazeb to Regeneron Pharmaceuticals with an indication for the treatment of infection caused by Zaire ebolavirus in October 2020. [2] [6] The drug has also received orphan drug designation from the European Medicines Agency. [23]
By Pratik Jain (Reuters) -Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat ...
A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper copycat drugs, analysts said. Shares of Regeneron rose 1.7% ...
[1] [2] It was developed by Regeneron Pharmaceuticals. [1] The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea. [1] Odronextamab was approved for medical use in the European Union in August 2024. [1] [2]
Ad
related to: regeneron approved drugs